LobbyingNational Organization for Rare Disorders lobbying by quarter
National Organization for Rare Disorders's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $160K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
National Organization for Rare Disorders
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $160K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $50K | 1 |
| Q1 2023 | $50K | 1 |
| Q2 2023 | $30K | 1 |
| Q3 2023 | $30K | 1 |
| Q4 2023 | $30K | 1 |
| Q1 2024 | $60K | 1 |
| Q2 2024 | $70K | 1 |
| Q3 2024 | $60K | 1 |
| Q4 2024 | $50K | 1 |
| Q1 2025 | $50K | 1 |
| Q2 2025 | $60K | 1 |
| Q3 2025 | $60K | 1 |
| Q4 2025 | $30K | 1 |
| Q1 2026 | $80K | 1 |
| Q2 2026 | $50K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$215K · 15 reports
- Medicare and Medicaid$215K · 15 reports
- Pharmacy$215K · 15 reports
- Budget and appropriations$115K · 9 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Centers For Medicare and Medicaid Services (CMS)14 reports
- Food & Drug Administration (FDA)9 reports
- Health & Human Services, Dept of (HHS)9 reports
- Natl Institutes of Health (NIH)3 reports
- Natl Institute of Standards & Technology (NIST)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseNational Organization for Rare Disorders | $760K | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $50K |
| 04/15for Q1 | In-house | $80K |
| 01/20for Q4 2025 | In-house | $30K |
| 25/10/20for Q3 2025 | In-house | $60K |
| 25/07/23for Q2 2025 | In-house | $60K |
| 25/07/21for Q2 2025 | In-house | $50K |
| 25/04/16for Q1 2025 | In-house | $50K |
| 25/01/20for Q4 2024 | In-house | $50K |
| 24/10/15for Q3 2024 | In-house | $60K |
| 24/07/16for Q2 2024 | In-house | $70K |
| 24/04/17for Q1 2024 | In-house | $60K |
| 24/01/19for Q4 2023 | In-house | $30K |
| 23/10/19for Q3 2023 | In-house | $30K |
| 23/07/20for Q2 2023 | In-house | $30K |
| 23/04/19for Q1 2023 | In-house | $50K |
| 23/01/20for Q4 2022 | In-house | $50K |